TY - JOUR
T1 - Response to
T2 - “Commentary on: phosphodiesterase type 5 inhibitors do not prevent curvature progression but shorten pain duration in the active phase of Peyronie’s disease
AU - Durukan, Emil
AU - Jensen, Christian Fuglesang Skjødt
AU - Fode, Mikkel
PY - 2024
Y1 - 2024
N2 - We appreciate the commentary by Manfredi et al. on our study investigating the impact of phosphodiesterase type 5 inhibitors (PDE5is) on Peyronie’s disease (PD) in the active phase [1]. The attention devoted to non-surgical interventions in PD in recent years highlights a growing recognition of the need for effective non-invasive treatments for this condition. This increased focus may reflect a broader shift in medical practice towards holistic patient care, emphasizing options beyond surgical intervention. Despite the paucity of clinical studies, PDE5is hold promise as a viable, safe, and practical approach to managing the condition, potentially offering relief and influencing its progression [2, 3]. With their generally well-tolerated nature and favorable safety profile [4], PDE5is emerge as an appealing choice for PD management
AB - We appreciate the commentary by Manfredi et al. on our study investigating the impact of phosphodiesterase type 5 inhibitors (PDE5is) on Peyronie’s disease (PD) in the active phase [1]. The attention devoted to non-surgical interventions in PD in recent years highlights a growing recognition of the need for effective non-invasive treatments for this condition. This increased focus may reflect a broader shift in medical practice towards holistic patient care, emphasizing options beyond surgical intervention. Despite the paucity of clinical studies, PDE5is hold promise as a viable, safe, and practical approach to managing the condition, potentially offering relief and influencing its progression [2, 3]. With their generally well-tolerated nature and favorable safety profile [4], PDE5is emerge as an appealing choice for PD management
U2 - 10.1038/s41443-024-00872-z
DO - 10.1038/s41443-024-00872-z
M3 - Comment/debate
C2 - 38519589
AN - SCOPUS:85188469468
SN - 0955-9930
VL - 36
SP - 297
EP - 298
JO - International Journal of Impotence Research
JF - International Journal of Impotence Research
IS - 3
ER -